Harbour BioMed
Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer.
Launch date
Employees
Market cap
€91.2m
Enterprise valuation
€28m (Public information from Sep 2024)
Share price
HKD1.23 2142.HK
Cambridge Massachusetts (HQ)
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 5.4m | 14.1m | 4.3m | 40.7m | 89.5m | 659m | 930m |
% growth | - | 160 % | (69 %) | 844 % | 120 % | 636 % | 41 % |
EBITDA | (62.9m) | (291m) | (131m) | (115m) | 32.2m | - | - |
% EBITDA margin | (1161 %) | (2062 %) | (3042 %) | (284 %) | 36 % | - | - |
Profit | (67.5m) | (296m) | (138m) | (137m) | 22.8m | - | - |
% profit margin | (1245 %) | (2101 %) | (3198 %) | (337 %) | 25 % | - | - |
R&D budget | 49.5m | 55.2m | 107m | 135m | 45.1m | - | - |
R&D % of revenue | 913 % | 392 % | 2486 % | 332 % | 50 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
$50.0m | Series A | ||
N/A | N/A | Series A | |
* | $85.0m | Series B | |
* | $75.0m | Series B | |
$103m | Series C | ||
N/A | $221m | IPO | |
Total Funding | €284m |
Recent News about Harbour BioMed
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Harbour BioMed
EditACQUISITION by Harbour BioMed Dec 2016